INTRODUCTION
Adrenocortical carcinoma (ACC) is a rare and aggressive tumor with an annual incidence between 0.7 and 2 cases per million. ACC is more frequently detected in women (55-60%) and certain age groups (fourth and fifth decades); however, ACC can occur at any age 1 . ACC can affect children, with an exceedingly high incidence reported in southern Brazil, due to the high prevalence of a TP53 germline mutation 2 . ACCs most frequently present as sporadic tumors, but can be encountered in the setting of hereditary tumor syndromes, such as Li Fraumeni (TP53 germline and somatic mutations), familial adenomatous polyposis coli (β-catenin somatic mutations) and Beckwith-Wiedeman (IGF-2 overexpression) 3 .
Patients with ACC have an extremely poor prognosis, with an overall 5-year survival rate between 16 and 47% 4 . Prognosis is mainly influenced by completeness of surgical removal and tumor stage at diagnosis, with a 5-year stage-dependent survival of 81, 61, 50, and 13 %, respectively, from stage 1 to stage 4 5 . However, ACC is a heterogeneous disease with variable survival at any stage depending on molecular, pathological and clinical factors that have only been partially ellucidated 6 . One of the factors influencing the clinical phenotype of ACC patients is the functional activity of the tumor, which may result in different endocrine syndromes 3, 4, 6 . Manifestations of adrenal steroid hormone excess represent the most common presentation of ACC in up to 60% of cases 4 (Figure 1) . Patients with non-functioning ACC present with back or abdominal pain, nausea, vomiting, or less frequently fever and weigh loss. Also, in an increasing number of patients, ACC is discovered serendipitously, due to the widespread application of high-resolution cross-sectional scans 7 .
CLINICAL PRESENTATION
ACC has the propensity to produce and secrete steroids; thus, in all patients with a suspected ACC, signs and symptoms of cortisol, aldosterone, and sex steroids should be actively investigated 4 (Box 1). Concomitant secretion of different steroids is a hallmark of ACC. Pure estrogen excess is rare and may cause gynecomastia, loss of libido and testicular atrophy in men 8 .
Patients with cortisol-secreting ACC exhibit facial plethora, easy bruising, weight gain, proximal myopathy, severe hypertension and uncontrolled diabetes mellitus. Hypokalemia is common with severe hypercortisolism because mineralocorticoid receptors are triggered by the large amount of cortisol that overwhelms the inactivating capacity of corticosteroid 11β-dehydrogenase isoenzyme 2 (HSD11B2). Women frequently complain of acne, hirsutism, and oligomenorrhea 4 . The differential diagnosis in these situations is PCOS, especially with mild or subclinical hypercortisolism. Clinical clues that are helpful to the diagnosis of ACC are the concomitant existence of Cushingoid phenotype with signs of marked androgen excess, or Cushing phenotype along with cancer-related symptoms (anorexia, cachexia, mass effect).
With rapidly growing tumors, cancer-related features dominate the clinical presentation. ACC can also cause deep venous thrombosis or pulmonary embolism due to either cortisol excess or malignancy 4 . Cortisol excess should be excluded in all patients with suspected ACC, even if they don't harbor typical cushingoid features 9 . Specific findings at CT scan, such as large mass size, high density (>10 Hounsfield Units), intra-tumoral necrosis, irregular shape and margins should raise the suspect of an ACC (Figure 2 ).
Box 1. Clinical manifestations
• Concomitant secretion of multiple steroids is a hallmark of ACC
• Hypercortisolism in the most frequent endocrine abnormality in ACC, although can present with catabolic features due to rapidly progressive malignancy
• Manifestations of hypercortisolism in ACC can be mild or subclinical, and erroneously attributed of PCOS
• Flank pain and constitutive symptoms are frequent in "incidental" ACC
ENDOCRINE ASSESSMENT
A detailed hormonal work-up ( promoted this definition to the classic "subclinical Cushing's syndrome" 9 . Autonomous cortisol secretion is certain for a cortisol levels above 5 μg/dL after 1-mg DST, while values between 1.8 μg/dL and 5 μg/dL require additional investigation to confirm the diagnosis.
These include plasma ACTH and UFC levels as well as a thorough evaluation of clinical conditions potentially associated with cortisol excess (i.e. arterial hypertension, diabetes, obesity). Recognizing asymptomatic cortisol excess preoperatively identifies the patients who benefit from glucocorticoid replacement after adrenalectomy 13 .
Aldosterone-producing ACC is rare and is generally associated with severe hypertension and marked hypokalemia 14 . Screening for hyperaldosteronism by measuring of plasma aldosterone and plasma renin activity (PRA) (or direct renin concentration) is recommended in all hypertensive and/or hypokalemic patients with adrenal masses 15 . In some cases, pseudo-aldosteronism is present, due to increased production of deoxycorticosterone .
Hypersecretion of sexual steroids is frequently observed in ACC patients. Estrogens excess should be ascertained in males (especially in cases of gynecomastia) and post-menopausal females. Baseline 17-OH progesterone levels are frequently increased, as well as androstenedione and DHEAS, which leads to increased plasma testosterone in females 4 .
Measurement of steroid precursors in blood or urine may be exploited for diagnostic purposes. However, the value of increased DHEAS levels to predict malignancy of an adrenal mass is rather low 16 . More recently, it was demonstrated that serum steroid paneling by LC-MS/MS is a useful tool to discriminate ACC from other adrenal tumor lesions. In this study, both the number of steroids secreted in high amounts and the marked elevation of several steroid intermediates without biological activity was characteristic of ACC and useful for the differential diagnosis. The cortisol precursor 11-deoxycortisol was found the most discriminating between ACC and non-ACC adrenal lesions 17 .
Assessment of plasma or urine fractionated metanephrines is recommend in patients with suspected ACC to exclude a pheochromocytoma, and avoid misdiagnosis and unexpected intraoperative complications 4, 7, 9 . Pertinently, a pheochromocytoma may appear as a large, heterogeneous and hypervascularized mass mimicking ACC. [3] [4] [5] . It has been recently established that the proliferation activity of the tumor influences the risk of recurrence following R0 surgery.
Assessment of the proliferation index Ki-67 is currently used to assess proliferation, despite some problems to harmonize immunohistochemical readings among different pathologists. In a European multicenter study, a Ki-67 value at 10% was found to separate patients at good or worse prognosis with a hazard ratio of recurrence of 1.042 per each % increase 18 The role of overt cortisol excess as a negative prognostic factor has been first suggested in an Italian study 19 There are several possible underlying mechanisms by which excess cortisol influences the prognosis in ACC patients. First, hypercortisolism is associated with increased morbidity and mortality 24 which complicates the management of ACC patients (Box 1). Second, although an association between cortisol secretion and tumor grading has not been demonstrated so far, tumors with cortisol production may be more aggressive. This was supported by a French study evaluating the role of SKG1 protein expression in ACC 25 . SKG1 is a glucocorticoidinducible kinase involved in cell cycle progression, acting as an anti-apoptotic factor. The study demonstrated an inverse association between SGK1 expression and cortisol overproduction 25 . Low SGK1 protein level was identified as a negative prognostic factor in ACC patients, being associated with reduced OS (HR: 2.0, 1.24-3.24; P < 0.005). Third, the immunosuppressive effects of overt cortisol excess before surgery may favor the development of ACC micrometastases and recurrences.
Of note, studies implicating hypercortisolism as a negative predictive factor were retrospective and used variable methods used to confirm cortisol excess. However, they suggest that cortisol excess in ACC may identify a cluster of patients who need more active surveillance and treatment (Figure 3) .
Box 2. Implications of cortisol excess on ACC prognosis
• Most studies indicated that overt cortisol excess is associated with a detrimental prognosis
• Risk of recurrence after surgery is higher for cortisol-secreting ACC The risk for recurrence is lower for patients who undergo surgery by expert surgeons 29 but cannot be not prevent completely prevented. More than 50% of the tumors that have been completely extirpated are doomed to relapse 30 and most patients with ACC recurrence experience further tumor progression and eventually die of the disease. These outcomes and the significant propensity of ACC to recur provide a rationale for adjuvant therapies.
Mitotane (o,p'-DDD, an isomer of the insecticide dichlorodiphenyltrichloroethane -DDT), is an
orally administered adrenolytic drug. The first report of the destruction of the zona fasciculata and zona reticularis in the adrenal gland of dogs receiving mitotane was written in 1960 and demonstrated a marked reduction of glucocorticoids and 17-hydroxycorticosteroids in basal conditions and after ACTH stimulation 31 . Following this observation, it was found that mitotane is able to inhibit gene expression of a variety of cytochrome P450-dependent mitochondrial enzymes of the steroidogenetic pathway, including 20,22 desmolase (CYP11A1), 11β-hydroxylase (CYP11B1) and 18β-hydrolase (CYP11B2) 32 . Critical steps of the inhibitory effects on steroidogenesis may occur in mitochondria possibly involving CYP11A1, a mitochondrial enzyme that catalyzes the transformation of cholesterol to pregnenolone 33 .
The net effect is an inhibition of adrenal steroid production; thus, mitotane may ameliorate signs and symptoms of cortisol excess, and for this reason this adrenolytic drug has been used as a medical treatment of all causes of Cushing's syndrome 34 .
Although randomized controlled trials on the use of adjuvant mitotane in ACC patients following radical surgery are still unavailable, a large retrospective case-control study reported that patients treated with adjuvant mitotane had a significantly longer recurrencefree survival and overall survival compared with two independent groups of patients left untreated following surgery 35 . Recently, the same group has updated the follow-up of these cohorts of patients with almost 10 years of additional observation, confirming that adjuvant mitotane treatment is associated with a significant benefit in terms of recurrence-free survival regardless of the hormone secretory status 36 . In this study, median recurrence-free survival was of 42 months in the adjuvant group compared with 17 months in control group 1 (p<0.001) and 26 months control group 2 (p<0.005) 36 . Despite its retrospective nature, this study remains the most informative positive study on the topic and represents a reference for decision making on adjuvant therapy. However, literature is conflicting and there is also evidence of a relative ineffectiveness of adjuvant mitotane. A recent multicenter study concluded that adjuvant mitotane was associated with decreased recurrence-free survival and overall survival. However, patients treated with mitotane had worse prognostic factors than untreated patients (more stage IV and more secreting ACCs in the mitotane group) 37 .
During the 60s and 70s, mitotane was used for the treatment of patients with non-operable ACC, with evidence of reduction of the tumor mass and control of the symptoms related to hormonal hypersecretion. However, despite some isolated cases of complete tumor regression 38 , most patients showed only a partial and transient response 39 hormone secreting ACC, since it has both an inhibitory effect on adrenal steroidogenesis and a cytotoxic effect on the tumor, although its success rate in controlling hormone excess is not well known 3, 10 . Mitotane is characterized by a slow onset of action, linked to the building of adequate plasma levels, which means treatment should initially include rapidly effective steroidogenesis inhibitors such as metyrapone, ketoconazole, etomidate 48 . However, mitotane is a strong inducer of CYP3A4 activity 49 and this may cause drug interactions when used in a combination therapy. The safety profile of the accompanying drugs should also be carefully considered to avoid cumulative toxicity with mitotane (i.e. gastrointestinal and liver toxicity).
A series of 14 patients with severe hypercortisolism, including 8 ACC, have been treated with a combination of metyrapone and ketoconazole in two tertiary-care university hospitals. In patients with ACC, median UFC after 1 week of treatment fell from 16.0 to 1. 48, 53 . In this study, the addition of metyrapone to EDP-M led to a rapid resolution of symptoms and signs of Cushing's syndrome and a significant improvement of the patient conditions. This finding has to be underlined because EDP-M usually requires several weeks to attain a control of hypercortisolism. Metyrapone was well tolerated, did not increase the toxicity of the EDP-M regimen, and did not alter EDP-M efficacy in terms of tumor control. Therefore, this combination may represent a rapid, effective and well-tolerated treatment of overt Cushing sustained by ACC.
Because of the adrenolytic effect of mitotane, all patients should receive glucocorticoid replacement to prevent adrenal insufficiency. Steroid doses are typically higher than in Addison's disease, due to an enhanced metabolic clearance rate of glucocorticoids induced by mitotane 3, 4 . It was calculated that mitotane is able to inactivate 50% of administered hydrocortisone through enhanced CYP3A enzyme activity 55 . An inadequate treatment of adrenal insufficiency increases mitotane-related toxicity, particularly gastrointestinal side effects, and reduces tolerance 56 . Mineralocorticoid supplementation is not mandatory in all patients because the zona glomerulosa is partly spared by the toxic effect of mitotane 56 .
Conclusions
Adrenocortical carcinoma may present frequently with Cushing's syndrome that may have atypical features. Cushing's syndrome is ACTH-independent and the concomitance of cortisol and androgen excess is a clue to suspect the diagnosis. When an adrenocortical carcinoma is associated with cortisol excess its prognosis is worse compared to non-secretory tumors, even if complete resection is attained. Tumors causing hypercortisolism have a higher risk of recurrence. Moreover, Cushing's syndrome carries a huge disease burden in case of advanced adrenocortical carcinoma and complicates management. Controlling cortisol excess is an urgent need that may be accomplished before giving chemotherapy to overcame the enhanced risk of infections. Mitotane is the mainstay of medical treatment of hypercortisolism;
however, its delayed action calls for associating more rapid agents. The inhibitor of steroidogenesis metyrapone has been used successfully in this contest.
Box 3. Therapy for ACC with hypercortisolemia
• Surgery is the treatment of choice of ACC when radical resection is feasible and is associated with improved oncological and endocrinological outcomes
• Despite radical surgery, ACC has a high recurrence rate and mitotane is frequently used as a post-operative adjunctive treatment
• Advanced or inoperable ACC is treated with mitotane alone or in combination with chemotherapy depending on patient and tumor characteristics 
